vs
Comstock Holding Companies, Inc.（CHCI）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
Comstock Holding Companies, Inc.的季度营收约是STANDARD BIOTOOLS INC.的1.2倍（$23.9M vs $19.6M），Comstock Holding Companies, Inc.净利率更高（56.3% vs -177.4%，领先233.7%），Comstock Holding Companies, Inc.同比增速更快（41.5% vs -11.5%），过去两年Comstock Holding Companies, Inc.的营收复合增速更高（50.0% vs -12.2%）
该条目原介绍康斯托克矿脉的地理与发现背景，并非企业经营信息，康斯托克控股公司是一家美国企业，相关公开经营业务信息暂缺。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
CHCI vs LAB — 直观对比
营收规模更大
CHCI
是对方的1.2倍
$19.6M
营收增速更快
CHCI
高出53.0%
-11.5%
净利率更高
CHCI
高出233.7%
-177.4%
两年增速更快
CHCI
近两年复合增速
-12.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.9M | $19.6M |
| 净利润 | $13.5M | $-34.7M |
| 毛利率 | 35.5% | 48.5% |
| 营业利润率 | 32.4% | -168.5% |
| 净利率 | 56.3% | -177.4% |
| 营收同比 | 41.5% | -11.5% |
| 净利润同比 | 30.5% | -28.8% |
| 每股收益（稀释后） | — | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CHCILAB
| Q4 25 | $23.9M | — | ||
| Q3 25 | $13.3M | $19.6M | ||
| Q2 25 | $13.0M | $21.8M | ||
| Q1 25 | $12.6M | $40.8M | ||
| Q4 24 | $16.9M | — | ||
| Q3 24 | $13.0M | $22.1M | ||
| Q2 24 | $10.8M | $22.5M | ||
| Q1 24 | $10.6M | $45.5M |
净利润CHCILAB
| Q4 25 | $13.5M | — | ||
| Q3 25 | $541.0K | $-34.7M | ||
| Q2 25 | $1.4M | $-33.5M | ||
| Q1 25 | $1.6M | $-26.0M | ||
| Q4 24 | $10.3M | — | ||
| Q3 24 | $2.4M | $-26.9M | ||
| Q2 24 | $946.0K | $-45.7M | ||
| Q1 24 | $910.0K | $-32.2M |
毛利率CHCILAB
| Q4 25 | 35.5% | — | ||
| Q3 25 | 11.0% | 48.5% | ||
| Q2 25 | 19.0% | 48.8% | ||
| Q1 25 | 18.6% | 48.4% | ||
| Q4 24 | 33.4% | — | ||
| Q3 24 | 26.3% | 54.9% | ||
| Q2 24 | 17.2% | 46.1% | ||
| Q1 24 | 16.5% | 53.1% |
营业利润率CHCILAB
| Q4 25 | 32.4% | — | ||
| Q3 25 | 5.0% | -168.5% | ||
| Q2 25 | 13.7% | -118.1% | ||
| Q1 25 | 13.7% | -80.8% | ||
| Q4 24 | 30.1% | — | ||
| Q3 24 | 21.8% | -120.9% | ||
| Q2 24 | 11.4% | -134.5% | ||
| Q1 24 | 10.8% | -132.2% |
净利率CHCILAB
| Q4 25 | 56.3% | — | ||
| Q3 25 | 4.1% | -177.4% | ||
| Q2 25 | 11.1% | -153.7% | ||
| Q1 25 | 12.6% | -63.8% | ||
| Q4 24 | 61.1% | — | ||
| Q3 24 | 18.3% | -122.0% | ||
| Q2 24 | 8.8% | -203.3% | ||
| Q1 24 | 8.6% | -70.6% |
每股收益（稀释后）CHCILAB
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.09 | ||
| Q2 25 | — | $-0.09 | ||
| Q1 25 | — | $-0.07 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.07 | ||
| Q2 24 | — | $-0.12 | ||
| Q1 24 | $0.09 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $31.3M | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $70.0M | $399.7M |
| 总资产 | $85.0M | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CHCILAB
| Q4 25 | $31.3M | — | ||
| Q3 25 | $26.2M | $129.4M | ||
| Q2 25 | $30.5M | $158.6M | ||
| Q1 25 | $28.3M | $150.9M | ||
| Q4 24 | $28.8M | — | ||
| Q3 24 | $21.1M | $210.6M | ||
| Q2 24 | $17.4M | $269.8M | ||
| Q1 24 | $16.2M | $287.1M |
总债务CHCILAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益CHCILAB
| Q4 25 | $70.0M | — | ||
| Q3 25 | $56.3M | $399.7M | ||
| Q2 25 | $55.5M | $424.5M | ||
| Q1 25 | $53.7M | $454.6M | ||
| Q4 24 | $52.4M | — | ||
| Q3 24 | $41.7M | $489.3M | ||
| Q2 24 | $39.2M | $510.3M | ||
| Q1 24 | $37.9M | $577.3M |
总资产CHCILAB
| Q4 25 | $85.0M | — | ||
| Q3 25 | $67.6M | $539.6M | ||
| Q2 25 | $65.2M | $557.0M | ||
| Q1 25 | $62.8M | $579.6M | ||
| Q4 24 | $64.9M | — | ||
| Q3 24 | $52.2M | $681.5M | ||
| Q2 24 | $48.6M | $708.7M | ||
| Q1 24 | $46.8M | $777.7M |
负债/权益比CHCILAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.8M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-23.1M |
| 自由现金流率自由现金流/营收 | — | -118.1% |
| 资本支出强度资本支出/营收 | — | 4.5% |
| 现金转化率经营现金流/净利润 | 0.36× | — |
| 过去12个月自由现金流最近4个季度 | — | $-111.1M |
8季度趋势，按日历期对齐
经营现金流CHCILAB
| Q4 25 | $4.8M | — | ||
| Q3 25 | $-3.2M | $-22.2M | ||
| Q2 25 | $2.2M | $-20.7M | ||
| Q1 25 | $582.0K | $-30.3M | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $3.9M | $-27.9M | ||
| Q2 24 | $1.3M | $-39.0M | ||
| Q1 24 | $-2.2M | $-62.5M |
自由现金流CHCILAB
| Q4 25 | — | — | ||
| Q3 25 | — | $-23.1M | ||
| Q2 25 | — | $-22.6M | ||
| Q1 25 | — | $-35.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-30.1M | ||
| Q2 24 | — | $-41.0M | ||
| Q1 24 | — | $-63.3M |
自由现金流率CHCILAB
| Q4 25 | — | — | ||
| Q3 25 | — | -118.1% | ||
| Q2 25 | — | -103.6% | ||
| Q1 25 | — | -86.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -136.4% | ||
| Q2 24 | — | -182.2% | ||
| Q1 24 | — | -138.9% |
资本支出强度CHCILAB
| Q4 25 | — | — | ||
| Q3 25 | — | 4.5% | ||
| Q2 25 | — | 8.7% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 10.2% | ||
| Q2 24 | — | 8.6% | ||
| Q1 24 | — | 1.7% |
现金转化率CHCILAB
| Q4 25 | 0.36× | — | ||
| Q3 25 | -5.96× | — | ||
| Q2 25 | 1.51× | — | ||
| Q1 25 | 0.37× | — | ||
| Q4 24 | 1.03× | — | ||
| Q3 24 | 1.63× | — | ||
| Q2 24 | 1.35× | — | ||
| Q1 24 | -2.46× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CHCI
| Related Party | $22.1M | 92% |
| Nonrelated Party | $1.9M | 8% |
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
